These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 37656656)

  • 1. Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set.
    Ganie MA; Rashid A; Baba MS; Zargar MA; Wani IA; Nisar S; Wani IA; Douhath S; Sriwastawa M; Geer MI; Asrar MM; Kutum R; Hassan S; Khan S; Rafi W; Bhat DA; Showkat W; Sahar T; Choh NA; Khurshid R; Mudassar S; Shah ZA; Shabir I; Sofi SA; Gupta N; Hafeez I; Sreenivas V
    Clin Endocrinol (Oxf); 2023 Dec; 99(6):566-578. PubMed ID: 37656656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome.
    Wen X; Wang L; Bai E
    Front Endocrinol (Lausanne); 2024; 15():1370578. PubMed ID: 39109080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
    Ezeh U; Ezeh C; Pisarska MD; Azziz R
    Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
    Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study.
    Koch T; Doherty DA; Dickinson JE; Juul A; Hart R; Bräuner EV; Hickey M
    Psychoneuroendocrinology; 2021 Mar; 125():105104. PubMed ID: 33352473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
    Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
    Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features.
    Welt CK; Gudmundsson JA; Arason G; Adams J; Palsdottir H; Gudlaugsdottir G; Ingadottir G; Crowley WF
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4842-8. PubMed ID: 17003085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study.
    Skiba MA; Bell RJ; Herbert D; Garcia AM; Islam RM; Davis SR
    Hum Reprod; 2021 May; 36(6):1611-1620. PubMed ID: 33846715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
    Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome.
    Kim JJ; Hwang KR; Chae SJ; Yoon SH; Choi YM
    Hum Reprod; 2020 Mar; 35(3):652-659. PubMed ID: 32211797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.
    Kim JJ; Hwang KR; Lee D; Kim S; Choi YM
    Hum Reprod; 2024 May; 39(5):1072-1077. PubMed ID: 38514450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome.
    Ezeh U; Chen YI; Pall M; Buyalos RP; Chan JL; Pisarska MD; Azziz R
    Fertil Steril; 2024 Jun; 121(6):1040-1052. PubMed ID: 38307453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
    Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
    Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.